Novocure Q2 revenue up 6%, beats analyst estimates

Overview

• Novocure Q2 2025 revenue rises 6% yr/yr, beating analyst expectations

• Company reports Q2 net loss of $40.1 mln, with EPS at $0.36

• Gross margin declines to 74% due to new product rollout and tariffs

Outlook

• Novocure plans PMA submission for pancreatic cancer treatment in Q3 2025

• Company expects PMA submission for brain metastases from NSCLC in H2 2025

• Topline data from PANOVA-4 trial expected in H1 2026

• Topline data from TRIDENT trial expected in H1 2026

Result Drivers

• PATIENT GROWTH - Revenue increase driven by growth in active patient numbers across major markets

• PRODUCT LAUNCHES - Gross margin decline attributed to new product rollout and increased tariffs

• EXPENSES - Higher costs in research, development, and sales due to clinical trial ramp-ups and NSCLC sales force expansion

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Novocure Ltd is $33.00, about 50% above its July 23 closing price of $16.51

Press Release: ID:nBw6B75nqa